CRPS Treatment: pain in right arm for 6 months

Home / CRPS Case Studies Report

CRPS Treatment: pain in right arm for 6 months

Contents

General details and patient's info

Gender:Male.
Age:20 years old at the time of treatment.
Home Country:United Kingdom.
Illness duration:6 months prior to the Neridronate Treatment.
Cause:Surgery on right hand.
Symptoms:Stabbing pain; burning sensation; skin sensitivity; change in temperature are frequent in the right arm; hand gets red during flares up.
Clinical evaluation:CRPS. 
Time of treatment:July 2022.

Why the Patient decided to undergo the CRPS Treatment in Italy

The patient’s father had been looking online for treatments when he came by our website and learned about Neridronate. We had a call with both the patient and his father, after which they decided to move forward with the treatment. 

Medical treatment the Patient underwent in Italy

Complex regional pain syndrome (CRPS) is a severely painful and disabling disease for which a multitude of therapeutic interventions have been proposed. In the past two decades, only Bisphosphonates gained credibility. In recent years, more convincing evidence has become available on the use of Parenteral Neridronate. Since 2014, this drug is registered and marketed in Italy for the treatment of CRPS. To date, the only therapeutic schedule that is recognized to be able to confer benefit is the intravenous (IV) administration of 100 mg given 4 times.

4 neridronate infusions (100mg, I.v. in saline Solution 0,9% 250 ml)

See the Official Study on the Oxford Academics website: https://academic.oup.com/rheumatology/article/52/3/534/1777330

3 sessions Neuromuscular Rehabilitation Treatment Treatment with Physiotherapist.
Rehabilitation therapy is a full body workout which focuses on the general wellbeing of the body, to help the affected limb get back to its normal self.

7 days Light Therapy (in hotel room, 30+ more minutes each day)
30 minutes or more of usage of the MTI Light Therapy reduces inflammation, increase micro-circulation, relax nerves and muscles, reduces pain transmission, accelerates healing, regenerates cells, and promotes cells activation.

Daily Report

DAY 1: Arrival at the Verona airport, greeted by his Patient Manager, followed by check-in at his Hotel in Verona. Briefing focused on the next days.

DAY 2: Rest day in the hotel, in contact with his Patient Manager.

DAY 3: Morning pick-up by his Patient Manager, 1st visit with the Rheumatologist Professor, 1st Rehabilitation session, and 1st infusions.

DAY 4: Morning pick-up by his Patient Manager, 2nd infusions.

DAY 5: Morning pick-up by his Patient Manager, 2nd Rehabilitation session and 3rd infusions.

DAY 6: Rest day in the hotel, in contact with his Patient Manager.

DAY 7: Morning pick-up by his Patient Manager, 3rd Rehabilitation session, 4th infusions and 2nd visit with the Rheumatologist Professor.

DAY 8: Pick-up by his Patient Manager, check-out, and drop-off at the Verona airport for his trip back home.

Follow up

OCTOBER 2022 (3 months after Neridronate treatment): Patient feels the sensitivity has improved drastically and his pain levels are getting lower week by week.

DECEMBER 2022 (4 months after Neridronate treatment): Patient reports 90% disappearance of all symptoms.

OCTOBER 2023 (more than a year after Neridronate treatment): The patient has called us for his Patient Manager’s birthday! He mentions being in full remission in the call, which we couldn’t be happier about.

Conclusion

Getting access to the treatment in the first year after the CRPS onset is always the best of choices. As shown in the original study, and in this particular case of a 20 years old patient, it very often lead to a full remission of all symptoms.
Return to Case Study reports
Contact us for the evaluation of your case

DISCLAIMER
This is not a medical case study; it merely describes each patient’s journey, and it omits all personal data. The people who redacted it are not doctors but all the facts reported are objective and represent the patient’s reality thanks to the information in our possession. The report is not part of any clinical trials. It was written to provide more information to patients who have made multiple requests for treatment outcomes of cases like theirs.